Winnipeg, Manitoba – June 6th, 2014: The Centre for Drug Research and Development (CDRD), Canada’s national drug development and commercialization centre, headquartered in Vancouver, is pleased to announce that it has entered into a new Affiliation Agreement with the University of Manitoba (U of M), opening the door for health researchers at the University to now collaborate with CDRD’s drug development and commercialization experts, and access its specialized platform supporting the development of both small molecule and biologic therapeutics across a broad spectrum of disease indications.
This partnership builds on CDRD’s previously-established relationship with the St. Boniface Hospital Research – a research campus that includes the Dr. Andrei Sakharov MRI Centre and the I.H. Asper Clinical Research Institute, synergistically integrating excellence in medical care with cutting-edge research. These partnerships solidify CDRD’s reach into Manitoba – the eighth Canadian province in which it now has active collaborations.
CDRD President and CEO, Karimah Es Sabar commented, “As western Canada’s very first university, the University of Manitoba has a long history and esteemed place on the Canadian research landscape, so we are very pleased to be able to announce this new partnership today. Academic research is the lifeblood of Canada’s health sciences sector, but in order to bring the full societal benefits of that research to Canadians, we must have an avenue to translate it into new therapies. Through our partnerships with the U of M and St. Boniface Hospital Research, we have an enhanced means to carry-out such translation on some of Canada’s top research generated in Manitoba.”
“This new partnership will assist faculty members in moving their research from the lab into practice,” says Dr. Digvir Jayas, Vice-President (Research and International) and Distinguished Professor at the University of Manitoba. “The resources and expertise will allow us to better assess technologies and move them through proof of concept to developers who can bring the products to market, effectively translating ideas into practice.”
Since becoming fully operational in 2008, CDRD has evaluated some 825 Canadian and international health research projects for their commercial/therapeutic potential, subsequently carrying-out development on 125, and successfully advancing 47 through multiple scientific milestones and value-creation points, enabling 10 commercial transactions – and in doing so, firmly establishing itself a robust Canadian commercialization engine for the health sciences, supporting an estimated 2165 direct and indirect jobs, and contributing $119M back to the GDP.
For additional information, please contact:
The Centre for Drug Research and Development (CDRD)
Direct: (604) 827-1223